Kenneth JC Lim, Haematologist at Northern Health and the Victorian Cancer Cytogenetic Service, shared a post on LinkedIn about a recent article he and his colleagues co-authored, adding:
“In light of SOC CAR-T therapy possibly being made available for Australian patients with Multiple Myeloma in the future.
IEC- associated delayed neurotoxicity has to be better understood!”
Title: Clinical course, risk factors and mitigating strategies for Immune effector cell-associated late onset neurotoxicities after ciltacabtagene autoleucel CAR-T in multiple myeloma
Authors: Kenneth J. C. Lim, Melinda Tan, Ricardo Parrondo, Saurabh Chhabra, Katharine Dooley, Andre De Menezes Silva Corraes, Darin Carabenciov, Morie Gertz, Lisa Hwa, Stephens Haily, Prashant Kapoor, Taxiarchis Kourelis, Rahma Warsame, Joselle Cook, Moritz Binder, P. Leif Bergsagel, Udit Yadav, Erin Wiedmeier-Nutor, Susan Geyer, Sikander Ailawadhi, Rafael Fonseca, Shaji Kumar, Anastasia Zekeridou, Yi Lin
Read the Full Article on Blood Cancer Journal
More posts about Multiple Myeloma.